ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
ESMO 2023 – Pluvicto’s big splash gets an early preview
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Triple meeting 2023 – a p53 double-whammy for PMV
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
Tempest kicks up a storm as Morpheus strikes again
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.
